J.W. Cole Advisors, Inc. Savara Inc Transaction History

J.W. Cole Advisors, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Jun 10, 2022	SELL	$1.05 - $1.36 $3,255 - $4,216	-3,100 Reduced 23.66%	10,000 $13,000
Q1 2022 May 16, 2022	BUY	$1.05 - $1.36 $3,255 - $4,216	3,100 Added 31.0%	13,100 $10,000
Q4 2021 Jan 25, 2022	SELL	$1.04 - $1.34 $100 - $129	-97 Reduced 0.96%	10,000 $12,000
Q3 2021 Oct 26, 2021	BUY	$1.18 - $1.64 $11,914 - $16,559	10,097 New	10,097 $14,000

128

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $365M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of J.W. Cole Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on J.W. Cole Advisors, Inc. with notifications on news.